RNS Number : 3336X
Oxford Biomedica PLC
24 June 2008
For Immediate Release 24 JUNE 2008
OXFORD BIOMEDICA TO PRESENT AT JEFFERIES HEALTHCARE CONFERENCE
Oxford, UK - 24 June 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company,
today announces that Nick Woolf, the Company's
SVP Corporate Strategy, will present a company update on Wednesday, 25 June 2008 at 2:00 pm
ET/ 7:00 pm BST at the Jefferies 2nd Annual
Healthcare Conference being held in New York.
The presentation will be webcast live and may be accessed under the investors section of
the Company's website,
www.oxfordbiomedica.co.uk. The presentation will also be available for replay.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000
JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Tel: +44 (0)20 7466 5000
Johnson Buchanan Communications
Scientific/Trade Press Enquiries:
Holly Griffiths/ Katja Stout/ Claire Mosley Tel: +44 (0)20 7457 2020
College Hill Life Sciences
US Enquiries:
Thomas Fechtner Tel: (646) 378 2900
The Trout Group LLC
Notes to editors
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer
immunotherapy and gene-based therapies. The Company
was established in 1995, as a spin-out from Oxford University, and is listed on the London
Stock Exchange.
The Company has a platform of gene delivery technologies, which are based on highly
engineered viral systems. Oxford BioMedica also has
in-house clinical, regulatory and manufacturing know-how. The lead product candidate is
TroVax®, a therapeutic vaccine for multiple solid
cancers, which is licensed to sanofi-aventis for global development and commercialisation.TroVax is in Phase III development. Oxford
BioMedica has three other products in clinical development, including ProSavin®, a novel
gene-based treatment for Parkinson's disease, in a
Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one
of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with
sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and
Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.
Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUOUVRWORNUAR
|